Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Editor's pick

08-08-2017 | Non-small cell lung cancer | At a glance | Article

At a glance: The KEYNOTE lung cancer trials

Here is our updated quick-access guide to the KEYNOTE trials investigating the anti-PD-1 agent pembrolizumab in the non-small-cell and small-cell lung cancer settings.

Updated July 2019

13-08-2019 | Prostate cancer | Highlight | News

Meta-analysis supports MRI plus targeted biopsy for prostate cancer diagnosis

Prebiopsy multiparametric magnetic resonance imaging plus targeted biopsy is associated with increased detection of clinically significant prostate cancer versus ultrasonography-guided systematic biopsy alone, study data show.

18-06-2019 | CNS metastases | Video | Article

Managing brain metastases in lung cancer

Brain metastases are a common complication of lung cancer and are associated with significant morbidity and mortality. In this video, Manmeet Ahluwalia provides a neuro-oncologist's perspective on managing lung cancer patients who develop these metastases. 

These videos were made possible by independent educational funding provided by AstraZeneca.


Upcoming symposium

Simplifying the sequencing of treatment in NSCLC patients with no actionable mutations

Simplifying the sequencing of treatment in NSCLC patients with no actionable mutations

Specialty

Latest from across the site

16-08-2019 | EMA | News

EMA adopts new indications for pembrolizumab, atezolizumab

Click through to find out which additional patient groups can now receive these drugs

15-08-2019 | Urothelial cancer | News

Gemcitabine–eribulin shows promise for cisplatin-ineligible urothelial carcinoma

Phase II study data suggest favorable treatment response and survival with first-line gemcitabine–eribulin in cisplatin-ineligible patients with metastatic urothelial carcinoma.

14-08-2019 | Non-small cell lung cancer | News

Nivolumab shows long-term clinical efficacy in Japanese patients with advanced NSCLC

Pooled long-term results from two multicenter phase II studies indicate that nivolumab is efficacious in Japanese patients with previously treated, stage IIIB/IV squamous or nonsquamous non-small-cell lung cancer.

13-08-2019 | Non-small cell lung cancer | Article

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

Camidge DR et al. Nat Rev Clin Oncol 2019; 16(6): 341-355. doi:10.1038/s41571-019-0173-9.

13-08-2019 | Prostate cancer | Highlight | News

Meta-analysis supports MRI plus targeted biopsy for prostate cancer diagnosis

Prebiopsy multiparametric magnetic resonance imaging plus targeted biopsy is associated with increased detection of clinically significant prostate cancer versus ultrasonography-guided systematic biopsy alone, study data show.

12-08-2019 | Checkpoint blockade | News

Individuals with autoimmune disease ‘good candidates’ for cancer immunotherapy

A French database analysis lends further support for the use immune checkpoint inhibitors for cancer in patients with pre-existing autoimmune disease.

Meet the Editorial Board


Our international Editorial Board members Dr Fiona Blackhall (Christie Hospital, Manchester, UK) and Dr Axel Merseburger (University Hospital Schleswig-Holstein, Germany) work closely with the editorial team to highlight gaps in coverage and select topics to feature on this digital platform.

Why register? Medicine Matters oncology is a free resource providing the latest news and clinical guidance

Register today and receive updates directly to your inbox!
Medicine Matters oncology has been specifically developed for the time-limited healthcare professional who is looking for a single resource providing credible information on current practice and the latest advances in oncology.
Already registered? Log in now to unlock your access.

Latest from us on Twitter

Updates from oncology organizations

New Content Item Meet our Advisory Board

Image Credits